【24h】

Type 2 diabetes and metabolic syndrome - adipokine levels and effect of drugs

机译:2型糖尿病和代谢综合征 - adipokine水平和药物的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Type 2 diabetes mellitus (T2DM) is a consequence of complex interactions among multiple genetic variants and environmental risk factors. This complex disorder is also characterized by changes in various adipokines. In this study, our objective was to estimate the levels of adiponectin, leptin, and resistin (ALR) in T2DM patients, besides studying the effect of various drugs on their levels. Study participants included 400 diabetic and 300 normal patients from the Department of Endocrinology and Department of Biochemistry, Govt Medical College Srinagar. Subjects were categorized under various groups, i.e., Group 1 (metformin treated) and Group 2 (glimepiride treated), and cases were also categorized as obese with T2DM (Group A), obese without T2DM (Group B), and T2DM only (Group C). The serum ALR levels were estimated by ELISA (Alere), and biochemical parameters were also evaluated before and after treatment. Adiponectin levels were found to be significantly lower in T2DM cases as compared to controls (125.5 versus 22.5 +/- 7.9g/ml), while leptin and resistin levels were found to be significantly higher than controls (14.3 +/- 7.4 versus 7.36 +/- 3.73ng/ml) (13.4 +/- 1.56 versus 7.236 +/- 2.129pg/ml). Taking the effect of drugs into consideration, the effect on adiponectin and resistin levels was found to be highly significant in Group 2 before and after treatment (11 +/- 5 versus 19.2 +/- 4.5g/ml) (13.6 +/- 2.5 versus 7.3 +/- 2.9pg/ml), while more effect was observed in leptin among Group 1 (metformin)-treated cases (27 +/- 15ng/ml versus 15 +/- 15ng/ml). Further the adiponectin levels were found to be significantly lower in Group B, while leptin and resistin levels were found to be significantly higher among obese cases when compared to T2DM cases only. Glimepiride also shows more effect on FBG, HbA1c% levels, while metformin shows more effect on Lipid profile levels. From the study, it can be concluded that ALR levels are affected by use of antidiabetic drugs among which glimepiride shows more effect on adiponectin and resistin levels, while leptin gets affected more by metformin. It can also be proposed that ALR levels are not affected by diabetes only, suggesting that their alterations in T2DM may be due to obesity as we observed more ALR changes in obese cases when compared to T2DM cases, and so there might be an important link between adiposity and insulin resistance.
机译:2型糖尿病(T2DM)是多种遗传变异和环境风险因素之间复杂的相互作用的结果。这种复杂的疾病的特征还具有各种adipokines的变化。在这项研究中,我们的目标是估计T2DM患者的脂联素,瘦素和抵抗水平,除了研究各种药物对其水平的影响。学习参与者包括400名糖尿病和300名患有内分泌和生物化学系,政府医学院僧伽的生物化学系。受试者在各种组下进行分类,即第1组(二甲双胍治疗)和第2组(胶质素酰亚的子处理),以及病例也被分类为肥胖的T2DM(A组),没有T2DM(B组)和T2DM的肥胖(B组)和T2DM(组C)。 ELISA(Salere)估计血清ALR水平,并且在治疗之前和之后也评估生化参数。与对照(125.5对22.5 +/- 7.9g / ml)相比,在T2DM病例中发现脂联素水平显着降低,而瘦素和抗蛋白水平明显高于对照(14.3 +/- 7.4与7.36 + / - 3.73ng / ml)(13.4 +/- 1.56与7.236 +/- 2.129pg / ml)。考虑到药物的效果,发现治疗前后2组对脂联素和抗性水平的影响(11 +/- 5与19.2 +/- 4.5g / ml)(13.6 +/- 2.5)与7.3 +/- 2.9pg / ml),而第1组(二甲双胍) - 治疗病例(27 +/- 15ng / ml与15 +/- 15ng / ml)之间的瘦素观察到更多效果。此外,B组中发现脂联素水平显着降低,而瘦蛋白和抗蛋白水平仅在与T2DM案件相比时明显更高。 Glimepiride还对FBG,HBA1C%水平的影响更多,而二甲双胍对脂质分布水平的影响更多。从研究来看,可以得出结论,ALR水平受到抗糖尿病药物的影响,其中胶质珠肽对脂联素和抵抗蛋白水平产生更多影响,而瘦素受到二甲双胍的影响。它也可以提出,ALR水平仅受糖尿病的影响,表明它们在T2DM中的改变可能是由于肥胖,因为我们观察到T2DM案件的肥胖病例的更大变化,因此可能存在一个重要的联系肥胖和胰岛素抵抗力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号